cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Shahdevi Nandar Kurniawan
Contact Email
shahdevinandar@ub.ac.id
Phone
+62341-321297
Journal Mail Official
jphv@ub.ac.id
Editorial Address
Neurology Department, Faculty of Medicine, Brawijaya University Jl. JA Suprapto No. 2 Malang, Indonesia 65112
Location
Kota malang,
Jawa timur
INDONESIA
Journal of Pain, Vertigo and Headache
Published by Universitas Brawijaya
ISSN : 27233979     EISSN : 27233960     DOI : https://doi.org/10.21776/ub.jphv
Core Subject : Science,
Neuroscience
JPHV - Journal of Pain, Headache and Vertigo is a peer-reviewed and open access journal that focuses on promoting pain, headache and vertigo. This journal publishes original articles, reviews, and also interesting case reports. JPHV - Journal of Pain, Headache and Vertigo is an international scientific journal, published twice a year by PERDOSSI (Perhimpunan Dokter Spesialis Saraf Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia.
Arjuna Subject : Ilmu Syaraf - Neorologi
Articles 92 Documents
 6   7   8   9   10 
RIVASTIGMINE TRANSDERMAL PATCH FOR ALZHEIMER’S DISEASE: A SYSTEMATIC REVIEW Baskoro, Firza Yoga; Hassa, Nazwan; Hajar, Nabil; Balqis, Indira Aura
Journal of Pain, Headache and Vertigo Vol. 6 No. 2 (2025): September
Publisher : PERDOSNI (Perhimpunan Dokter Spesialis Neurologi Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/

Abstract

Background: Alzheimer's disease (AD) is the most common type of dementia disease. Acetylcholinesterase inhibitors (AChE-I) plays a pivotal role by increasing acetylcholine levels in the brain to improve cognitive function of Alzheimer's patients. Several agents including cholinesterase inhibitors such as donepezil and galantamine, as well as the NMDA receptor antagonist memantine are known for its benefit in increasing acetylcoline . However, Rivastigmin is the only AChE-I agent available in patch preparation. Objective : This study aims to evaluate the efficacy of Rivastigmin patch in improving cognitive function using the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) in Alzheimer's disease patients. Methods: This research was conducted in accordance with the Systematic Review without Meta-Analysis (SWiM) guideline. A systematic database search was conducted in Medline, Google Scholar, and Cochrane Central Libraries using a pre-determined search query. Articles were screened by independent reviewers for eligibility to be included in the study. After risk of bias was conducted, seven studies were included for this research. Results: The included studies reported varied outcomes regarding cognitive improvement in Alzheimer's disease (AD) patients, depending on the dosage of Rivastigmine used. Overall, Rivastigmine was found to slow the progression of cognitive decline, as measured by the ADAS-Cog, and in some cases, even reduced ADAS-Cog scores by up to 3 points . Rivastigmine patch is known to inhibit the action of acetylcholinesterase enzyme which causes degradation of acetylcholine in the synapse gap, ultimately improving the cognitive of AD patients. Studies also mention that Rivasitgmine patch preparation has better tolerance to side effects compared to capsules or placebo. Conclusion: Rivastigmine patch shows improvement of cognitive status in Alzheimer's patients and has good tolerability compared to placebo or capsule preparations. the long-term efficacy and safety of the rivastigmine patch remain underexplored, and the generalizability of the findings to diverse patient populations is uncertain.
PATHOPHYSIOLOGY, DIAGNOSIS, AND MANAGEMENT OF NEUROPATHIC PAIN Puteri, Lintang Firdhani Nabila; Rahmawati, Dessika
Journal of Pain, Headache and Vertigo Vol. 6 No. 2 (2025): September
Publisher : PERDOSNI (Perhimpunan Dokter Spesialis Neurologi Indonesia Cabang Malang) - Indonesian Neurological Association Branch of Malang cooperated with Neurology Residency Program, Faculty of Medicine Brawijaya University, Malang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/

Abstract

Background: Neuropathic pain is a type of chronic pain resulting from lesions or disorders of the somatosensory nervous system. This condition is often difficult to recognize and manage due to the complexity of its mechanisms and the variation in clinical symptoms. Objective: This article aims to review the pathophysiological mechanisms, diagnostic approaches, and management strategies for neuropathic pain based on current scientific literature. Result: The main mechanisms of neuropathic pain include ectopic activity, central sensitization, dysfunction of descending inhibitory pathways, and glial cell activation. Diagnosis is established through a combination of detailed history taking, neurological examination, screening tools such as DN4, and supporting investigations such as EMG-NCV, QST, skin biopsy, ultrasonography, and MRI. Pharmacological therapy includes the use of tricyclic antidepressants, SNRIs, anticonvulsants, and topical agents, with an individualized and stepwise approach. Advanced imaging techniques such as MRI and CT play a critical role in detecting structural lesions. Conclusion: The diagnostic and therapeutic approaches to neuropathic pain should be multimodal and mem-based. Integration of clinical and supporting examinations is key to improving diagnostic accuracy and therapeutic effectiveness.

Page 10 of 10 | Total Record : 92

 6   7   8   9   10 

Filter by Year

2020 2025


Reset
Filter By Issues
All Issue Vol. 6 No. 2 (2025): September Vol. 6 No. 1 (2025): March Vol. 5 No. 2 (2024): September Vol. 5 No. 1 (2024): March Vol. 4 No. 2 (2023): September Vol. 4 No. 1 (2023): March Vol. 3 No. 2 (2022): September Vol. 3 No. 1 (2022): March Vol. 2 No. 2 (2021): September Vol. 2 No. 1 (2021): March Vol. 1 No. 2 (2020): September Vol. 1 No. 1 (2020): March More Issue